

CSD/SE/BM-NOTICE/2025-26
March 27, 2026

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Intimation of Closure of Trading Window

Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Trading Window for dealing in the securities of the Company will be closed for the Designated Persons and their immediate relatives from April 1, 2026 and the same will remain closed till 48 hours after the declaration of Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ending March 31, 2026.

The date of the Board Meeting for consideration and approval of the Audited Financial Results for the Quarter and Year ending March 31, 2026 shall be informed in due course.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Himanshu Agarwal
Whole-time Director and Chief Financial Officer
(DIN: 06672915)

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

